Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study.

ABSTRACT:

Background

In Australia, prescribing restrictions limit access to internationally recommended second-line therapies such as rituximab and thrombopoietin agonists (TPO-A) (eltrombopag and romiplostim). Subsequent lines of therapy include an array of immunosuppressive and immune-modulating agents directed by drug availability and physician and patient preference.

Objectives

The objective of the study was to describe the use of first and subsequent lines of treatment for adult immune thrombocytopenia (ITP) in Australia and to assess their effectiveness and tolerability.

Patients/methods

A retrospective review of medical records was conducted of 322 patients treated for ITP at eight participating centers in Australia between 2013 and 2020. Data were analyzed by descriptiv

SUBMITTER: Rosenberg A 

PROVIDER: S-EPMC9483174 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature